Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease
STEP 变构抑制剂的开发作为阿尔茨海默病的新疗法
基本信息
- 批准号:10410545
- 负责人:
- 金额:$ 85.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:3xTg-AD mouseAMPA ReceptorsAcidsActive SitesAdverse effectsAllosteric SiteAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease therapeuticAttenuatedBackBehavioralBindingBiochemicalBiological AssayBlood - brain barrier anatomyCatalytic DomainCell LineCell modelCellsCharacteristicsChemicalsChemistryChronicCognitiveCognitive deficitsCollaborationsComputer ModelsCorpus striatum structureDNADataDevelopmentDiseaseDrug TargetingEarly treatmentEndocytosisEnsureExcretory functionFaceFamily memberFragile X SyndromeFunctional disorderGeneticGlutamate ReceptorGlutamatesGoalsHumanImpaired cognitionInstitutesKnock-outKnockout MiceLabelLengthLinkMetabolismMitogen-Activated Protein KinasesModelingMusN-Methyl-D-Aspartate ReceptorsNR2B NMDA receptorNeurodegenerative DisordersNeuronsOrganismParkinson DiseasePharmaceutical PreparationsPharmacologyPhospho-Specific AntibodiesPhosphoric Monoester HydrolasesPhosphotransferasesPropertyProtein DephosphorylationProtein Tyrosine PhosphataseProteinsProto-Oncogene Proteins c-fynReportingSafetySchizophreniaSeriesSignal TransductionSpecificityStructure-Activity RelationshipSulfhydryl CompoundsSurfaceSynapsesTechnologyTestingToxic effectX-Ray Crystallographyabsorptionbasedesigndrug discoveryefficacy testingexperiencehigh throughput screeningimprovedin vivoinduced pluripotent stem cellinhibitorinnovationlead seriesmouse modelneuropsychiatric disordernew therapeutic targetnovelnovel therapeuticsp38 Mitogen Activated Protein Kinasephosphatase inhibitorpostsynapticreceptorscaffoldscreeningsmall moleculesuccesssynaptic functiontargeted treatmenttreatment strategy
项目摘要
PROJECT SUMMARY
STriatal-Enriched Tyrosine Phosphatase (STEP) is a neuron-specific protein tyrosine phosphatase (PTP) and a
novel therapeutic target for Alzheimer's disease (AD), a debilitating neurodegenerative disorder for which
currently no cure exists. Recent studies indicate that STEP is overactive in AD and other neurodegenerative and
neuropsychiatric disorders. The emergent model suggests that the increase in STEP activity interferes with
synaptic function and contributes to the characteristic cognitive and behavioral deficits in these diseases.
Knockout or pharmacological inhibition of STEP in a mouse model of AD decreases the biochemical and
cognitive deficits in these mice, validating STEP as a novel drug target for the treatment of AD. However, the
only reported STEP inhibitor with cellular and in vivo activity is a benzopentathiepin (TC-2153) that is known to
modify DNA, thus likely causing adverse effects when given chronically. In this proposal we plan to develop the
first selective and drug-like inhibitors of STEP for proof-of-concept (POC) studies in AD mouse models. Previous
efforts to generate more drug-like STEP inhibitors have failed. These prior high-throughput screening (HTS)
efforts utilized simple biochemical screening assays with truncated STEP constructs that only contained the
catalytic domain. Thus, they favored the identification of compounds that target the highly conserved active site
and are not selective for STEP. We have developed a robust HTS platform based on protein thermal shift (PTS)
technology that can detect small molecule binding to full-length STEP in 384-well format. A sequence of
secondary assays to further characterize hits is in place, as well as crucial collaborations, ensuring the greatest
likelihood of success in the search for small molecules that are suitable for POC studies aimed at establishing a
STEP-based treatment strategy in AD. In Aim 1 we will perform HTS for STEP allosteric inhibitors using our PTS-
based screening platform. We will confirm and characterize hit compounds and select the most promising
scaffolds for chemical optimization in Aim 2, where we will improve STEP inhibitor potency, selectivity, and drug-
like properties. In Aim 3, we will evaluate selected inhibitors in cellular models for efficacy and specificity. Our
overall goal is to develop at least one lead series and one back-up series of potent and specific STEP inhibitor
probes that are ready for subsequent testing and optimization for in vivo studies.
项目摘要
富含酪氨酸的酪氨酸磷酸酶(STEP)是一种神经元特异性蛋白酪氨酸磷酸酶(PTP),
阿尔茨海默病(AD)的新治疗靶点,阿尔茨海默病是一种使人衰弱的神经退行性疾病,
目前没有治愈方法。最近的研究表明,STEP在AD和其他神经退行性疾病中过度活跃,
神经精神障碍涌现模型表明,STEP活动的增加干扰了
突触功能,并有助于这些疾病的特征性认知和行为缺陷。
在AD小鼠模型中STEP的敲除或药理学抑制降低了AD小鼠模型中的生化和代谢。
这些小鼠的认知缺陷,验证STEP作为治疗AD的新型药物靶标。但
唯一报道的具有细胞和体内活性的STEP抑制剂是苯并噻庚因(TC-2153),已知其
修饰DNA,因此长期服用可能会引起不良反应。在本提案中,我们计划开发
首个STEP选择性和药物样抑制剂,用于AD小鼠模型的概念验证(POC)研究。先前
产生更多药物样STEP抑制剂的努力已经失败。这些先前的高通量筛选(HTS)
这些努力利用了简单的生物化学筛选测定,其具有仅含有
催化域因此,他们倾向于鉴定靶向高度保守的活性位点的化合物
对STEP没有选择性。我们已经开发了一个强大的基于蛋白质热位移(PTS)的HTS平台
该技术可以检测与384孔格式的全长STEP结合的小分子。的序列
进一步表征命中的二级分析已经到位,以及关键的合作,确保最大的
成功寻找适合POC研究的小分子的可能性,
AD中基于STEP的治疗策略。在目标1中,我们将使用我们的PTS对STEP变构抑制剂进行HTS-
基于筛选平台。我们将确认和表征命中化合物,并选择最有前途的
目标2中的化学优化支架,我们将提高STEP抑制剂的效力,选择性和药物-
比如财产在目标3中,我们将在细胞模型中评估所选抑制剂的疗效和特异性。我们
总体目标是开发至少一个先导系列和一个备用系列的强效和特异性STEP抑制剂
这些探针可用于后续的测试和优化,用于体内研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lutz Tautz其他文献
Lutz Tautz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lutz Tautz', 18)}}的其他基金
Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients
靶向 VHR 磷酸酶治疗 COVID-19 患者脓毒症
- 批准号:
10385773 - 财政年份:2021
- 资助金额:
$ 85.15万 - 项目类别:
Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients
靶向 VHR 磷酸酶治疗 COVID-19 患者脓毒症
- 批准号:
10213437 - 财政年份:2021
- 资助金额:
$ 85.15万 - 项目类别:
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease
STEP 变构抑制剂的开发作为阿尔茨海默病的新疗法
- 批准号:
10053075 - 财政年份:2020
- 资助金额:
$ 85.15万 - 项目类别:
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease
STEP 变构抑制剂的开发作为阿尔茨海默病的新疗法
- 批准号:
10260540 - 财政年份:2020
- 资助金额:
$ 85.15万 - 项目类别:
Allosteric inhibition of the SHP2 oncoprotein in breast cancer
乳腺癌中 SHP2 癌蛋白的变构抑制
- 批准号:
9101727 - 财政年份:2016
- 资助金额:
$ 85.15万 - 项目类别:
Allosteric inhibition of the SHP2 oncoprotein in breast cancer
乳腺癌中 SHP2 癌蛋白的变构抑制
- 批准号:
9251251 - 财政年份:2016
- 资助金额:
$ 85.15万 - 项目类别:
STEP inhibitors for intervention in Alzheimer's Disease
STEP 抑制剂干预阿尔茨海默病
- 批准号:
8208923 - 财政年份:2011
- 资助金额:
$ 85.15万 - 项目类别:
STEP inhibitors for intervention in Alzheimer's Disease
STEP 抑制剂干预阿尔茨海默病
- 批准号:
8306030 - 财政年份:2011
- 资助金额:
$ 85.15万 - 项目类别:
Novel Delivery Technology for Potential Drugs for Cervical Cancer
宫颈癌潜在药物的新型输送技术
- 批准号:
7554157 - 财政年份:2008
- 资助金额:
$ 85.15万 - 项目类别:
Novel Delivery Technology for Potential Drugs for Cervical Cancer
宫颈癌潜在药物的新型输送技术
- 批准号:
7362677 - 财政年份:2008
- 资助金额:
$ 85.15万 - 项目类别:
相似海外基金
Role of PSD-95-linked PDE4A5 in Regulation of AMPA Receptors
PSD-95 连接的 PDE4A5 在 AMPA 受体调节中的作用
- 批准号:
10829146 - 财政年份:2023
- 资助金额:
$ 85.15万 - 项目类别:
The role of AMPA receptors in critical period plasticity in the auditory cortex
AMPA 受体在听觉皮层关键期可塑性中的作用
- 批准号:
RGPIN-2018-06552 - 财政年份:2022
- 资助金额:
$ 85.15万 - 项目类别:
Discovery Grants Program - Individual
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors
离子型谷氨酸信号系统体内探针:AMPA 受体
- 批准号:
10584340 - 财政年份:2022
- 资助金额:
$ 85.15万 - 项目类别:
The role of AMPA receptors in critical period plasticity in the auditory cortex
AMPA 受体在听觉皮层关键期可塑性中的作用
- 批准号:
RGPIN-2018-06552 - 财政年份:2021
- 资助金额:
$ 85.15万 - 项目类别:
Discovery Grants Program - Individual
The role of AMPA receptors in critical period plasticity in the auditory cortex
AMPA 受体在听觉皮层关键期可塑性中的作用
- 批准号:
RGPIN-2018-06552 - 财政年份:2020
- 资助金额:
$ 85.15万 - 项目类别:
Discovery Grants Program - Individual
Binding of Endophilin Endocytic Proteins to AMPA Receptors and Neuronal Voltage-gated Potassium (Kv) Channels: Regulation of Synaptic Plasticity
内亲素内吞蛋白与 AMPA 受体和神经元电压门控钾 (Kv) 通道的结合:突触可塑性的调节
- 批准号:
RGPIN-2015-03850 - 财政年份:2019
- 资助金额:
$ 85.15万 - 项目类别:
Discovery Grants Program - Individual
The missing link: Opioid modulation of AMPA receptors
缺失的环节:阿片类药物对 AMPA 受体的调节
- 批准号:
2253144 - 财政年份:2019
- 资助金额:
$ 85.15万 - 项目类别:
Studentship
Calcium-permeable AMPA receptors and their auxiliary subunits: pharmacological and molecular intervention in health and disease
钙渗透性 AMPA 受体及其辅助亚基:健康和疾病的药理学和分子干预
- 批准号:
MR/T002506/1 - 财政年份:2019
- 资助金额:
$ 85.15万 - 项目类别:
Research Grant
The role of AMPA receptors in critical period plasticity in the auditory cortex
AMPA 受体在听觉皮层关键期可塑性中的作用
- 批准号:
RGPIN-2018-06552 - 财政年份:2019
- 资助金额:
$ 85.15万 - 项目类别:
Discovery Grants Program - Individual
Life cycle of AMPA receptors under acute metabolic stress
急性代谢应激下 AMPA 受体的生命周期
- 批准号:
411538084 - 财政年份:2018
- 资助金额:
$ 85.15万 - 项目类别:
Research Units